GlassScriptPhysician profile
Kelli B Baender
NPI 1093793416
$9,790.00
in general payments reported to CMS, 2019-2025
35 companies · $253 in 2025
The $253 reported for 2025 was less than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,581 · 2020: $623 · 2021: $933 · 2022: $2,843 · 2023: $1,434 · 2024: $2,123 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,709 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,709.33 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,042.72 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $1,597.48 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $549.33 | 2019-2024 | Dupixent, Libtayo |
| Genzyme Corporation | $545.27 | 2019-2024 | |
| Leo Pharma INC. | $532.25 | 2019-2025 | Adbry, Spevigo |
| Ucb, INC. | $465.07 | 2019-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $453.52 | 2019-2025 | Aklief, Nemluvio, Epsolay |
| Incyte Corporation | $432.11 | 2021-2024 | Opzelura |
| Janssen Biotech, INC. | $350.09 | 2020-2025 | Tremfya, Stelara, Remicade |
| Lilly USA, LLC | $347.91 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $316.61 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $278.84 | 2019-2024 | Winlevi, Ilumya |
| Amgen INC. | $201.23 | 2019-2024 | Otezla, Enbrel |
| Pfizer INC. | $200.21 | 2020-2024 | |
| Mayne Pharma Commercial LLC | $179.06 | 2021-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $174.42 | 2019-2024 | Siliq, Targretin, Duobrii |
| Almirall LLC | $172.88 | 2019-2024 | Seysara |
| Celgene Corporation | $165.89 | 2019 | |
| Prugen, INC. Pharmaceuticals | $143.38 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $106.26 | 2023-2025 | Zoryve |
| Epi Health, LLC | $93.31 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $59.96 | 2021 | |
| Allergan, INC. | $58.58 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.15 | 2023-2024 | Spevigo |
| Dermavant Sciences, INC. | $43.97 | 2023-2024 | Vtama |
| Biofrontera INC. | $35.82 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Organon LLC | $31.33 | 2025 | |
| Dermira, INC. | $30.34 | 2019 | |
| Vyne Pharmaceuticals INC. | $28.29 | 2021 | |
| Journey Medical Corporation | $21.28 | 2019 | |
| Alnylam Pharmaceuticals INC. | $20.92 | 2025 | Givlaari |
| Dusa Pharmaceuticals, INC. | $17.45 | 2019 | |
| Stemline Therapeutics INC. | $13.58 | 2020 | |
| Strata Skin Sciences, INC. | $13.01 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $11.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelli Baender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.